CapMan, Investor Growth Capital and Nobel Biocare are selling the Swedish MedTech company Entific to the Australian listed company Cochlear for SEK 1 050 million.

Entific was created in 1999 as a spin-off from the Swedish dental implant company Nobel Biocare and is today an international MedTech company that develops and markets hearing implants for rehabilitation of conductive and mixed hearing losses as well as Single Sided Deafness (SSD). Sales in 2004 reached SEK 211.5 million and the pre-tax earnings were SEK 37 million. Cochlear is a leading Australian MedTech company and develops and markets cochlear implants system for the treatment of profound deafness. Cochlear’s turnover is AUD 285.8 million which represents approx. SEK 1 540 million. The company is listed on the Australian Stock Exchange. ”The deal represents a perfect match and will give Entific a new larger platform to work from. It is a good solution for all the parties involved. Entific and Cochlear are complementary both from a company culture and product development point of view, but even more so as regards sales and marketing. The products of Entific and Cochlear target the same customer base and are sold to the same clinics and surgeons”, says Mr. Per Carendi, Chairman of the Board of Entific.